Influenza vaccine safe, effective during trastuzumab treatment for breast cancer

  • Joona TB & al.
  • Breast Cancer Res Treat
  • 1 Aug 2020

  • curated by Miriam Davis, PhD
  • Univadis Clinical Summaries
Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

Takeaway

  • Influenza vaccination was safe and effective during trastuzumab treatment in patients with HER2+ breast cancer participating in a nonrandomized Swedish trial.

Why this matters

  • Patients with cancer are at increased risk for infection because of immunosuppression caused by underlying malignancy or its treatment.
  • This trial provides empirical support for the current recommendation to offer influenza vaccination to patients with breast cancer being treated with targeted therapy.

Study design

  • Nonrandomized, open-label, multicenter trial of trivalent influenza vaccine administered to 20 patients with nonmetastatic breast cancer during trastuzumab treatment (midcycle) and 37 healthy control participants.
  • The vaccine contained inactivated A/California/7/2009 (H1N1) pdm09, A/Hongkong4801/2014 (H3N2), and B/Brisbane/60/2008.
  • Seroprotection rate was defined as at least 1:40 geometric mean titers of hemagglutination inhibition for H1N1 and influenza B strain.
  • Funding: UppsalaÖrebro Regional Research Council.

Key results

  • No difference in seroprotection rate between patients with breast cancer and control participants for:
    • H1N1: 100% in both groups.
    • Influenza B strain: 78.9% vs 89.2% (P=.423).
  • Both groups had an increase in geometric mean titers compared with baseline, and the increase was apparent at both 4 and 12 weeks after vaccination.
  • Adverse events were uncommon and mild in the breast cancer group; 1 serious adverse event unrelated to vaccination occurred.

Limitations

  • Nonrandomized, open-label design.
  • Small sample size.